Bugawan, Rodel B.
HRN: 22-81-55 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/01/2023
CEFUROXIME 1.5GM (VIAL)
04/01/2023
04/08/2023
IV
1.5g
Q8hours
Multiple Confluent Abrasions Sec To MVA
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes